Plus, news about Longevity Biomedical, Sensorion, Teva and Bristol Myers Squibb: Context Therapeutics buys a T cell engager: The biotech will pay $15 million upfront and up to $118.5 million in ...
Black Diamond Therapeutics’ stock price $BDTX jumped more than 15% premarket Monday morning after the company reported its ...
For AI-focused startups seeking out pharma deals, they have to go through people like Greg Meyers, the chief digital and ...
Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...
Australian radiopharma company Telix Pharmaceuticals is acquiring radioisotope manufacturer RLS Radiopharmacies in another ...
Ideaya Biosciences has set the stage on what a Phase 3 trial would look like for its rare eye cancer drug darovasertib, after ...
AstraZeneca, Daiichi’s TROP2 drug misses overall survival goal in Phase 3 breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...
As antibody–drug conjugates (ADCs) and immune checkpoint inhibitors continue to grab a lot of attention as transformative cancer therapies, they would appear to leave little room ...
The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback